Patrick van der Torre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrick van der Torre has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Marta Fiocco
Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands
4 shared publications - Tim Takken
University Medical Center Utrecht
4 shared publications Danielle Cataudella
Department of Pediatric Psychology, Children's Hospital, London Health Sciences Centre, London, ON, Canada
3 shared publicationsDeborah Tomlinson
Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada
3 shared publicationsEline van Dulmen-Den Broeder
VU University Medical Center Department of Pediatrics, Division of Oncology/Hematology PO Box 7057Room 6 D 120 Amsterdam Netherlands 1007 MB
3 shared publications- Emma Jacobine Verwaaijen
Princess Máxima Center, Utrecht, the Netherlands
3 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e77429
Prevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study
Background: Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined. Objective: This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects. Methods: This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation. Results: Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study. Conclusions: This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects. International Registered Report Identifier (IRRID): DERR1-10.2196/77429
- 16 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e77429
Open AccessPrevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study
Background: Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined. Objective: This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects. Methods: This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation. Results: Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study. Conclusions: This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects. International Registered Report Identifier (IRRID): DERR1-10.2196/77429
- Open Access
- 10 June 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12 (1) , e77766
Monitoring Steps and Heart Rate Using a Withings Smartwatch in Children and Adolescents With Cancer: Validation Study
Background: Consumer smartwatches offer potential for continuous monitoring of physical activity during childhood cancer treatment. However, their validity for measuring step count and heart rate in this population has not been established. Objective: This study examined the validity of a Withings smartwatch for monitoring step count and heart rate in children and adolescents undergoing cancer treatment. Methods: Children and adolescents aged 8 to 18 years under active cancer treatment wore a Withings smartwatch for 12 weeks. For validation purposes, children and adolescents simultaneously wore an ActiGraph wGT3X-BT accelerometer for 1 week under free-living conditions to assess step count agreement and were connected to a clinical heart rate monitor under resting conditions to assess heart rate agreement. Linear mixed models with participant ID as a random effect were used to estimate mean differences and derive 95% limits of agreement for repeated measurements. Results: A total of 14 children and adolescents participated in each of the validation analyses. The smartwatch recorded significantly fewer steps than the ActiGraph accelerometer for both steps per hour (mean difference 174 steps per hour; 95% limits of agreement=−283 to 633; P <.001) and steps per day (mean difference 3154 steps per day; 95% limits of agreement=−394 to 6702; P <.001), with increasing discrepancy at higher activity levels, suggesting proportional bias. No statistically significant difference in heart rate was observed between the smartwatch and the clinical heart rate monitor under resting conditions (mean difference −1.07 beats per minute; 95% limits of agreement=−17.55 to 15.41; P =.24). Conclusions: In children and adolescents undergoing cancer treatment, the Withings smartwatch showed minimal systematic bias for resting heart rate assessment, although individual variability was considerable. In contrast, step counts demonstrated systematic underestimation and wide limits of agreement compared with a research-grade accelerometer. The use of smartwatch-derived step counts for clinical benchmarking or goal setting in this population cannot currently be recommended.
- 10 June 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12 (1) , e77766
Open AccessMonitoring Steps and Heart Rate Using a Withings Smartwatch in Children and Adolescents With Cancer: Validation Study
Background: Consumer smartwatches offer potential for continuous monitoring of physical activity during childhood cancer treatment. However, their validity for measuring step count and heart rate in this population has not been established. Objective: This study examined the validity of a Withings smartwatch for monitoring step count and heart rate in children and adolescents undergoing cancer treatment. Methods: Children and adolescents aged 8 to 18 years under active cancer treatment wore a Withings smartwatch for 12 weeks. For validation purposes, children and adolescents simultaneously wore an ActiGraph wGT3X-BT accelerometer for 1 week under free-living conditions to assess step count agreement and were connected to a clinical heart rate monitor under resting conditions to assess heart rate agreement. Linear mixed models with participant ID as a random effect were used to estimate mean differences and derive 95% limits of agreement for repeated measurements. Results: A total of 14 children and adolescents participated in each of the validation analyses. The smartwatch recorded significantly fewer steps than the ActiGraph accelerometer for both steps per hour (mean difference 174 steps per hour; 95% limits of agreement=−283 to 633; P <.001) and steps per day (mean difference 3154 steps per day; 95% limits of agreement=−394 to 6702; P <.001), with increasing discrepancy at higher activity levels, suggesting proportional bias. No statistically significant difference in heart rate was observed between the smartwatch and the clinical heart rate monitor under resting conditions (mean difference −1.07 beats per minute; 95% limits of agreement=−17.55 to 15.41; P =.24). Conclusions: In children and adolescents undergoing cancer treatment, the Withings smartwatch showed minimal systematic bias for resting heart rate assessment, although individual variability was considerable. In contrast, step counts demonstrated systematic underestimation and wide limits of agreement compared with a research-grade accelerometer. The use of smartwatch-derived step counts for clinical benchmarking or goal setting in this population cannot currently be recommended.
- Open Access
- 27 August 2025
- Published by JMIR Publications Inc. in JMIR Pediatrics and Parenting
- Vol. 8 (1) , e75322
Feasibility, Barriers, and Facilitators of Long-Term Physical Activity Tracking During Treatment: Interview Study Among Childhood Cancer Patients
Background: Children with cancer are at risk of reduced physical activity. Gaining insight into physical activity using smartwatches could improve understanding of individual potential during treatment, support early recognition of aberrant physical activity, and enable tailored support. Objective: This study aimed to explore the feasibility, barriers, facilitators, and considerations of long-term physical activity tracking using a smartwatch during childhood cancer treatment. Methods: In this prospective study, 30 children (age 8‐18 years) under active cancer treatment were included in 2 phases. During phase 1, 15 children wore a smartwatch daily for 12 consecutive weeks, and in-depth interviews were conducted to identify principal considerations used to optimize wearability and the methods for phase 2. In phase 2, another 15 children wore the smartwatch, and semistructured interviews were conducted at weeks 1, 3, 6, and 12. These interviews were thematically analyzed to identify barriers and facilitators. An iterative process of alternating data collection and analysis allowed for ongoing method refinement and deepening thematic analysis during the study period. Results: Key considerations for improvement identified in phase 1 led to refinements in phase 2, including enhanced engagement, regular prompts, customized plans, personalized setup, and improved aesthetics and comfort. The interviews conducted during phase 2 identified barriers and facilitators. The 4 most prominent themes were burden and resilience, motivational drivers and perception, insight and evaluation, and user experience and functionality. Feasibility was influenced by the child’s physical state and perceived burden. Motivation, perceived value, and expectations played crucial roles in sustaining adherence, while also the balance between positive reinforcement and potential confrontation affected long-term use. User experience, including attractiveness, comfort, and usability, impacted acceptance. Conclusions: Real-time and long-term physical activity tracking using a smartwatch in children during cancer treatment was not feasible in our cohort. A personalized approach, incorporating individual preferences and physical condition, is essential to support adherence.
- 27 August 2025
- Published by JMIR Publications Inc. in JMIR Pediatrics and Parenting
- Vol. 8 (1) , e75322
Open AccessFeasibility, Barriers, and Facilitators of Long-Term Physical Activity Tracking During Treatment: Interview Study Among Childhood Cancer Patients
Background: Children with cancer are at risk of reduced physical activity. Gaining insight into physical activity using smartwatches could improve understanding of individual potential during treatment, support early recognition of aberrant physical activity, and enable tailored support. Objective: This study aimed to explore the feasibility, barriers, facilitators, and considerations of long-term physical activity tracking using a smartwatch during childhood cancer treatment. Methods: In this prospective study, 30 children (age 8‐18 years) under active cancer treatment were included in 2 phases. During phase 1, 15 children wore a smartwatch daily for 12 consecutive weeks, and in-depth interviews were conducted to identify principal considerations used to optimize wearability and the methods for phase 2. In phase 2, another 15 children wore the smartwatch, and semistructured interviews were conducted at weeks 1, 3, 6, and 12. These interviews were thematically analyzed to identify barriers and facilitators. An iterative process of alternating data collection and analysis allowed for ongoing method refinement and deepening thematic analysis during the study period. Results: Key considerations for improvement identified in phase 1 led to refinements in phase 2, including enhanced engagement, regular prompts, customized plans, personalized setup, and improved aesthetics and comfort. The interviews conducted during phase 2 identified barriers and facilitators. The 4 most prominent themes were burden and resilience, motivational drivers and perception, insight and evaluation, and user experience and functionality. Feasibility was influenced by the child’s physical state and perceived burden. Motivation, perceived value, and expectations played crucial roles in sustaining adherence, while also the balance between positive reinforcement and potential confrontation affected long-term use. User experience, including attractiveness, comfort, and usability, impacted acceptance. Conclusions: Real-time and long-term physical activity tracking using a smartwatch in children during cancer treatment was not feasible in our cohort. A personalized approach, incorporating individual preferences and physical condition, is essential to support adherence.
- Open Access
- 15 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Prevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study (Preprint)
BACKGROUND Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined. OBJECTIVE This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects. METHODS This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation. RESULTS Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study. CONCLUSIONS This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77429
- 15 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPrevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study (Preprint)
BACKGROUND Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined. OBJECTIVE This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects. METHODS This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation. RESULTS Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study. CONCLUSIONS This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77429
- Open Access
- 6 December 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (1) , 1-9
The views of parents of children with cancer and pediatric physical therapists on a network for continuity and optimal quality of care for children with cancer: KinderOncoNet
Purpose: Children with cancer require specific therapeutic guidance. Parents prefer physical therapy close to home, while pediatric physical therapists (PPTs) working in the community may lack specific knowledge. The aim of this study is to determine the needs of parents of children with cancer and PPTs to inform the design and development of a care network, named “KinderOncoNet.” Methods: We explored the perspectives and needs of parents of children with cancer and PPTs in the community, and we investigated the added value that KinderOncoNet could offer. We used an iterative process; data collection consisted of (1) gathering information from parents of children with cancer and PPTs through a survey and (2) co-creation sessions with stakeholders. Results: In total, 98 parents and 177 PPTs participated in the survey. Parents (97%) and PPTs (93%) indicated that the care network would bring added value. All but one parent stressed the importance of a local PPT being aware of both the condition and the side and late effects of oncological treatment. Moreover, 40% of PPTs thought they do not have sufficient knowledge to provide high-quality therapy and that they would embrace opportunities for education. Through the co-creation sessions, a prototype of the care network was conceptualized. Conclusion: KinderOncoNet can contribute to the continuity and quality of physiotherapy care for children with cancer during and after the oncological treatment. Such a network would allow for sharing knowledge, developing skills, and improving accessibility and communication in the Netherlands.
- 6 December 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (1) , 1-9
Open AccessThe views of parents of children with cancer and pediatric physical therapists on a network for continuity and optimal quality of care for children with cancer: KinderOncoNet
Purpose: Children with cancer require specific therapeutic guidance. Parents prefer physical therapy close to home, while pediatric physical therapists (PPTs) working in the community may lack specific knowledge. The aim of this study is to determine the needs of parents of children with cancer and PPTs to inform the design and development of a care network, named “KinderOncoNet.” Methods: We explored the perspectives and needs of parents of children with cancer and PPTs in the community, and we investigated the added value that KinderOncoNet could offer. We used an iterative process; data collection consisted of (1) gathering information from parents of children with cancer and PPTs through a survey and (2) co-creation sessions with stakeholders. Results: In total, 98 parents and 177 PPTs participated in the survey. Parents (97%) and PPTs (93%) indicated that the care network would bring added value. All but one parent stressed the importance of a local PPT being aware of both the condition and the side and late effects of oncological treatment. Moreover, 40% of PPTs thought they do not have sufficient knowledge to provide high-quality therapy and that they would embrace opportunities for education. Through the co-creation sessions, a prototype of the care network was conceptualized. Conclusion: KinderOncoNet can contribute to the continuity and quality of physiotherapy care for children with cancer during and after the oncological treatment. Such a network would allow for sharing knowledge, developing skills, and improving accessibility and communication in the Netherlands.
- Open Access
Novel Adaption of the SARC-F Score to Classify Pediatric Hemato-Oncology Patients with Functional Sarcopenia
Sarcopenia in pediatric hemato-oncology patients is undesirable because of the consequences it may have for treatment continuation and outcome, physical abilities and participation in daily life. An easy-to-use screening tool for sarcopenia will facilitate the identification of children at risk who need interventions to prevent serious physical deterioration. In the elderly, the use of the SARC-F score as a case-finding tool for sarcopenia is recommended. The aim of this cross-sectional study was to investigate the accuracy of the pediatric SARC-F (PED-SARC-F) for identifying sarcopenia in pediatric hemato-oncology patients, including the determination of a cut-off point for clinical use. Patients 3–20 years of age, under active treatment or within 12 months after treatment cessation were eligible. Patients had a physiotherapy assessment including a PED-SARC-F (0–10) and measurements of muscle strength (handheld dynamometry), physical performance (various tests) and/or muscle mass (bio-impedance analysis), as part of the standard of care. Spearman’s correlation coefficient (rs) between the PED-SARC-F and physiotherapy outcomes were calculated. Structural sarcopenia was defined as low appendicular skeletal muscle mass (ASMM) in combination with low muscle strength and/or low physical performance. Functional sarcopenia indicated low muscle strength combined with low physical performance. Multiple logistic regression models were estimated to study the associations between the PED-SARC-F and structural/functional sarcopenia. To evaluate which cut-off point provides the most accurate classification, the area under the receiver operating characteristic curve (AUCs), sensitivity and specificity per point were calculated. In total, 215 assessments were included, 62% were performed in boys and the median age was 12.9 years (interquartile range: 8.5–15.8). The PED-SARC-F scores correlated moderately with the measurements of muscle strength (rs = −0.37 to −0.47, p < 0.001) and physical performance (rs = −0.45 to −0.66, p < 0.001), and weakly with ASMM (rs = −0.27, p < 0.001). The PED-SARC-F had an AUC of 0.90 (95% confidence interval (CI) = 0.84–0.95) for functional sarcopenia and 0.79 (95% CI = 0.68–0.90) for structural sarcopenia. A cut-off point of ≥5 had the highest specificity of 96% and a sensitivity of 74%. In conclusion, we adapted the SARC-F to a pediatric version, confirmed its excellent diagnostic accuracy for identifying functional sarcopenia and defined a clinically useful cut-off point in pediatric hemato-oncology patients.
Open AccessNovel Adaption of the SARC-F Score to Classify Pediatric Hemato-Oncology Patients with Functional Sarcopenia
Sarcopenia in pediatric hemato-oncology patients is undesirable because of the consequences it may have for treatment continuation and outcome, physical abilities and participation in daily life. An easy-to-use screening tool for sarcopenia will facilitate the identification of children at risk who need interventions to prevent serious physical deterioration. In the elderly, the use of the SARC-F score as a case-finding tool for sarcopenia is recommended. The aim of this cross-sectional study was to investigate the accuracy of the pediatric SARC-F (PED-SARC-F) for identifying sarcopenia in pediatric hemato-oncology patients, including the determination of a cut-off point for clinical use. Patients 3–20 years of age, under active treatment or within 12 months after treatment cessation were eligible. Patients had a physiotherapy assessment including a PED-SARC-F (0–10) and measurements of muscle strength (handheld dynamometry), physical performance (various tests) and/or muscle mass (bio-impedance analysis), as part of the standard of care. Spearman’s correlation coefficient (rs) between the PED-SARC-F and physiotherapy outcomes were calculated. Structural sarcopenia was defined as low appendicular skeletal muscle mass (ASMM) in combination with low muscle strength and/or low physical performance. Functional sarcopenia indicated low muscle strength combined with low physical performance. Multiple logistic regression models were estimated to study the associations between the PED-SARC-F and structural/functional sarcopenia. To evaluate which cut-off point provides the most accurate classification, the area under the receiver operating characteristic curve (AUCs), sensitivity and specificity per point were calculated. In total, 215 assessments were included, 62% were performed in boys and the median age was 12.9 years (interquartile range: 8.5–15.8). The PED-SARC-F scores correlated moderately with the measurements of muscle strength (rs = −0.37 to −0.47, p < 0.001) and physical performance (rs = −0.45 to −0.66, p < 0.001), and weakly with ASMM (rs = −0.27, p < 0.001). The PED-SARC-F had an AUC of 0.90 (95% confidence interval (CI) = 0.84–0.95) for functional sarcopenia and 0.79 (95% CI = 0.68–0.90) for structural sarcopenia. A cut-off point of ≥5 had the highest specificity of 96% and a sensitivity of 74%. In conclusion, we adapted the SARC-F to a pediatric version, confirmed its excellent diagnostic accuracy for identifying functional sarcopenia and defined a clinically useful cut-off point in pediatric hemato-oncology patients.
- Open Access
- 20 January 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 619-629
Advancing the Field of Pediatric Exercise Oncology: Research and Innovation Needs
The field of pediatric exercise oncology explores the relationships between physical activity (PA), including exercise, and a range of outcomes among children and adolescents affected by cancer. Although PA is safe and beneficial for this population, several important gaps in knowledge and practice remain. In this article, we describe research and innovation needs that were developed with a team of international experts and relevant literature, a series of online surveys, and an in-person meeting. Addressing these needs will contribute valuable knowledge and practice outputs to advance this field, ultimately enabling a greater number of children and adolescents affected by cancer to realize the benefits of moving more.
- 20 January 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 619-629
Open AccessAdvancing the Field of Pediatric Exercise Oncology: Research and Innovation Needs
The field of pediatric exercise oncology explores the relationships between physical activity (PA), including exercise, and a range of outcomes among children and adolescents affected by cancer. Although PA is safe and beneficial for this population, several important gaps in knowledge and practice remain. In this article, we describe research and innovation needs that were developed with a team of international experts and relevant literature, a series of online surveys, and an in-person meeting. Addressing these needs will contribute valuable knowledge and practice outputs to advance this field, ultimately enabling a greater number of children and adolescents affected by cancer to realize the benefits of moving more.
- Open Access
- 1 December 2019
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 4 (4) , 82-88
Physical activity level objectively measured by accelerometery in children undergoing cancer treatment at home and in a hospital setting: A pilot study
- 1 December 2019
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 4 (4) , 82-88
Open AccessPhysical activity level objectively measured by accelerometery in children undergoing cancer treatment at home and in a hospital setting: A pilot study